AFJKU
Aimei Health Technology Co., Ltd
NasdaqGMUSDEQUITY
Financial Services
DELAYED
Last price
11.81
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
11.81
Day high
11.81
Day low
11.81
Volume
1.19K
Market cap
—
P/E (TTM)
—
52W range
7.60 – 80.00
Trailing performance
Returnvs SPY
1W
-1.58%
-0.2%
1M
-21.27%
-25.0%
3M
-78.46%
-81.6%
6M
-82.44%
-93.5%
YTD
-82.11%
-94.4%
1Y
+4.98%
-15.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AFJKU open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap—
Enterprise value$40.72M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$412.43K
EPS (TTM)—
Free cash flow$-892.17K
Total cash$1.47K
Total debt$3.33M
Book value / share$-1.42
Shares outstanding—
Float1.44M
Short % of float—
Dividend yield—
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-1.39%
Debt / equity—
Current ratio0.01
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Selling, general & admin | $835.76K | $1.06M | -21.5% |
| Total operating expense | $835.76K | $1.06M | -21.5% |
| Operating income | -$835.76K | -$1.06M | +21.5% |
| Net interest income | $1.90M | $3.62M | -47.6% |
| Pre-tax income | $1.06M | $2.55M | -58.5% |
| Net income | $1.06M | $2.55M | -58.5% |
| Net income to common | $1.06M | $2.55M | -58.5% |
| EBIT | -$835.76K | -$1.06M | +21.5% |
| EBITDA | -$835.76K | -$1.06M | +21.5% |
| Line item | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $2.93K | $28.21K | $580.72K | -89.6% |
| Cash & short-term investments | $2.93K | $28.21K | $580.72K | -89.6% |
| Total current assets | $2.93K | $30.38K | $580.72K | -90.4% |
| Total assets | $12.10M | $73.81M | $70.47M | -83.6% |
| Total current liabilities | $3.37M | $816.99K | $24.84K | +312.7% |
| Current debt | $2.02M | $227.70K | — | +788.9% |
| Total debt | $2.02M | $227.70K | — | +788.9% |
| Total liabilities | $4.06M | $1.51M | $714.84K | +169.5% |
| Retained earnings | -$4.06M | -$1.48M | -$134.34K | -174.8% |
| Shareholder equity | $8.04M | $72.31M | $69.76M | -88.9% |
| Working capital | -$3.37M | -$786.61K | $555.88K | -328.3% |
| Net tangible assets | $8.04M | $72.31M | $69.76M | -88.9% |
| Shares issued | 3.17M | 9.03M | 9.03M | -64.9% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | $1.06M | $2.55M | -58.5% |
| Change in working capital | $270.66K | $392.50K | -31.0% |
| Operating cash flow | -$565.10K | -$672.29K | +15.9% |
| Investing cash flow | $63.58M | -$277.70K | +22,995.2% |
| Share buybacks | -$65.33M | $0 | — |
| Financing cash flow | -$63.04M | $397.48K | -15,960.0% |
| Free cash flow | -$565.10K | -$672.29K | +15.9% |
| End cash position | $2.93K | $28.21K | -89.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Selling, general & admin | $61.98K | — | — | — | $413.41K | — |
| Total operating expense | $61.98K | $250.59K | $130.15K | $41.60K | $413.41K | -75.3% |
| Operating income | -$61.98K | -$250.59K | -$130.15K | -$41.60K | -$413.41K | +75.3% |
| Net interest income | $107.42K | $348.71K | $482.17K | $466.57K | $598.08K | -69.2% |
| Pre-tax income | $45.44K | $98.12K | $352.02K | $424.97K | $184.66K | -53.7% |
| Net income | $45.44K | $98.12K | $352.02K | $424.97K | $184.66K | -53.7% |
| Net income to common | $45.44K | $98.12K | $352.02K | $424.97K | $184.66K | -53.7% |
| EBIT | -$61.98K | -$250.59K | -$130.15K | -$41.60K | -$413.41K | +75.3% |
| EBITDA | -$61.98K | -$250.59K | -$130.15K | -$41.60K | -$413.41K | +75.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.52K | $2.93K | $2.98K | $2.14K | $7.34K | +532.2% |
| Cash & short-term investments | $18.52K | $2.93K | $2.98K | $2.14K | $7.34K | +532.2% |
| Total current assets | $18.71K | $2.93K | $24.95K | $44.64K | $8.02K | +538.7% |
| Total assets | $12.29M | $12.10M | $45.47M | $44.56M | $43.60M | +1.6% |
| Total current liabilities | $3.52M | $3.37M | $2.77M | $2.21M | $1.69M | +4.3% |
| Current debt | $2.09M | $2.02M | $1.66M | $1.21M | $755.40K | +3.4% |
| Total debt | $2.09M | $2.02M | $1.66M | $1.21M | $755.40K | +3.4% |
| Total liabilities | $4.21M | $4.06M | $3.46M | $2.90M | $2.38M | +3.6% |
| Retained earnings | -$4.19M | -$4.06M | -$3.44M | -$2.86M | -$2.37M | -3.2% |
| Shareholder equity | $8.09M | $8.04M | $42.00M | $41.65M | $41.23M | +0.6% |
| Working capital | -$3.50M | -$3.37M | -$2.75M | -$2.17M | -$1.68M | -3.9% |
| Net tangible assets | $8.09M | $8.04M | $42.00M | $41.65M | $41.23M | +0.6% |
| Shares issued | 3.17M | 3.17M | 6.12M | 6.12M | 6.12M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $45.44K | $98.12K | $352.02K | $424.97K | $184.66K | -53.7% |
| Change in working capital | -$12.63K | $207.36K | $34.04K | -$160.15K | $189.41K | -106.1% |
| Operating cash flow | -$74.61K | -$43.23K | -$96.11K | -$201.75K | -$224.01K | -72.6% |
| Investing cash flow | -$68.66K | $33.69M | -$450.00K | -$450.00K | $30.79M | -100.2% |
| Share buybacks | $0 | -$34.06M | $0 | $0 | -$31.27M | +100.0% |
| Financing cash flow | $158.86K | -$33.65M | $546.95K | $646.54K | -$30.58M | +100.5% |
| Free cash flow | -$74.61K | -$43.23K | -$96.11K | -$201.75K | -$224.01K | -72.6% |
| End cash position | $18.52K | $2.93K | $2.98K | $2.14K | $7.34K | +532.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.07%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.89
-0.63% from price
SMA 20
12.04
-1.94% from price
SMA 50
23.23
-49.17% from price
SMA 100
37.82
-68.77% from price
SMA 200
39.56
-70.15% from price
EMA 12
12.20
-3.16% from price
EMA 26
15.29
-22.76% from price
EMA 50
22.11
-46.59% from price
RSI (14)
13.5
Oversold
MACD (12,26,9)
-3.10
Hist 0.89
ATR (14)
0.10
0.85% of price
Realised vol 30D
157.8%
Annualised
Bollinger upper
13.42
20, 2σ
Bollinger lower
10.67
20, 2σ
50 / 200 cross
Death
23.23 vs 39.56
Trend bias
Below 200
-70.15%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.71
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
157.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-84.5%
Peak to trough
Max drawdown 5Y
-84.5%
Peak to trough
ATR 14
0.10
0.85% of price
Beta (reported)
0.90
5Y monthly, from filing
Short interest
Shares short
194
Prior 2.31K
Change vs prior
-91.6%
Shorts covering
% of float
—
—
% of shares out
—
Against total outstanding
Days to cover
0.1
Liquid
Float
1.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
SEC filings
Corporate Changes & Voting Matters
8-K · 2024-01-18
Tender Offer/Acquisition Reports
SC 13D · 2023-12-15
Corporate Changes & Voting Matters
8-K · 2023-12-12
Tender Offer/Acquisition Reports
SC 13G · 2023-12-08
Corporate Changes & Voting Matters
8-K · 2023-12-07
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2023-11-28
Offering Registrations
S-1/A · 2023-10-27
Offering Registrations
S-1/A · 2023-10-06
Headlines
Update: Aimei Health Technology Shares Fall After Terminating Merger Deal With United Hydrogen
MT Newswires · 45d ago
Top Midday Decliners
MT Newswires · 45d ago
Top Premarket Decliners
MT Newswires · 45d ago
Aimei Health Terminates Merger Deal With United Hydrogen Group; Shares Drop Pre-Bell
MT Newswires · 46d ago
AIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC.
GlobeNewswire · 46d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.